Learn about our healthcare areas

Explore medicine and therapy products
Explore MedTech products

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. Home/
      2. Media Center/
      3. Press releases /
      4. Innovative Medicine

      Innovative Medicine

      Innovative Medicine
      March 30, 2017

      Janssen Discontinues Development of Flubendazole Formulation to Treat Onchocerciasis

      Research supported Johnson & Johnson’s commitment to the 2012 London Declaration on Neglected Tropical Diseases and yielded important findings
      Learn more
      Global Health Equity
      March 23, 2017

      Johnson & Johnson Innovation launches Singapore QuickFire Challenge Competition in collaboration with ETPL and SMART to accelerate solutions for diabetes and other metabolic diseases

      Learn more
      Innovative Medicine
      March 18, 2017

      New Phase 3 Study Finds XARELTO® to Be Superior to Aspirin for Long-Term Prevention of Recurrent Blood Clots Without Observing any Significant Increase in Major Bleeding in Patients with Venous Thromboembolism

      Learn more
      Global Health Equity
      March 14, 2017

      Johnson & Johnson Reports that Investigational Ebola Vaccine Regimen Induced Durable Immune Response 1 Year After Vaccination in Phase 1 Study

      Learn more
      Global Health Equity
      March 14, 2017

      Johnson & Johnson Names Winners of First Africa Innovation Challenge

      Competition Part of Company’s Eighty-Five Year Commitment to Supporting Entrepreneurs, Science Education Opportunities, and Health Systems Across the Continent
      Learn more
      Innovative Medicine
      March 6, 2017

      Late-Breaking Results from XARELTO® (rivaroxaban) EINSTEIN CHOICE and GEMINI-ACS-1 Studies Among Research Accepted for Presentation at the American College of Cardiology 66th Annual Scientific Session

      Learn more
      Innovative Medicine
      March 3, 2017

      New Results From Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority Versus Humira® in Treatment of Moderate to Severe Plaque Psoriasis

      Additional Phase 3 Study Data Show Significant Efficacy of Guselkumab in Patients Experiencing Inadequate Response to STELARA® in the Treatment of Moderate to Severe Plaque Psoriasis
      Learn more
      Innovative Medicine
      February 24, 2017

      DARZALEX®▼ (daratumumab) Receives Positive CHMP Opinion for the Treatment of Multiple Myeloma in Patients who have Received At Least One Prior Therapy

      Janssen’s first-in-class CD38-directed monoclonal antibody now recommended for approval earlier in the treatment pathway in combination with two standard of care regimens
      Learn more
      Innovative Medicine
      February 14, 2017

      Janssen Announces Two-drug Combination of Dolutegravir and Rilpivirine Demonstrates Efficacy in Maintaining Viral Suppression in Phase III Clinical Studies

      First Detailed Results from SWORD Clinical Trial Program Show Investigational Two-drug Combination as Effective as Three- or Four-drug Regimens as Maintenance Therapy in Patients who have Already Achieved Viral Suppression
      Learn more
      Load More